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Abstract
Background: Initiating therapy with a low CD4 cell count is associated with a substantially greater risk of disease
progression and death than earlier initiation. We examined factors associated with late presentation of HIV using
the new European consensus definition (CD4 cell count <350 cells/mm3) and mortality.
Methods: Patients newly diagnosed with HIV infection at a UK clinic were recruited from January 1996 to May
2010. Factors associated with late presentation were assessed using logistic regression. Factors associated with
mortality rates were analysed using Poisson regression.
Results: Of the 1536 included in the analysis, 86% were male and 10% were aged 50 years and older. Half the
cohort (49%) had a CD4 cell count below 350 cells/mm3 at presentation (“late presentation”). The frequency of late
presentation was highest in those aged 50 years or older and remained unchanged over time (64.3% in 1996-1998
and 65.4% in 2008-2010). In contrast, among those aged less than 50 years, the proportion with late presentation
decreased over time (57.1% in 1996-1998 and 38.5% in 2008-2010). Other factors associated with late presentation
were African ethnicity and being a male heterosexual.
The mortality rate was 15.47/1000 person-years (pyrs) (95%-CI: 13.00-18.41). When compared with younger adults,
older individuals had a higher mortality, after adjusting for confounders (rate ratio (RR) = 2.87; 95%-CI: 1.88-4.40).
Conclusions: Older adults were more likely to present late and had a higher mortality. Initiatives to expand HIV
testing in clinical and community setting should not neglect individuals aged over 50.
Keywords: HIV, Late presentation, Older adults, Mortality, CD4 cell count
Background
Data from the Health Protection Agency (HPA) show
that about one-quarter of people with HIV infection in the
UK remain undiagnosed and 50% of adults diagnosed in
2010 had a CD4 cell count below 350/mm3 at diagnosis [1].
Initiating therapy with a CD4 cell count below 200 cells/
mm3 is associated with a substantially greater risk of disease
progression and death than earlier initiation [2]. Similarly,
individuals entering the Strategies for the Management of
Antiretroviral Therapy (SMART) study who were either
treatment-naive or who had not been on therapy for the
previous 6 months, and who deferred treatment until their
CD4 cell count was below 250 cells/mm3 had a more than
4 fold higher risk of opportunistic infections and serious
non-AIDS clinical events compared to patients who started
treatment with CD4 cell count above 350 cells/mm3 [3].
The SMART study [4] and other cohort studies [5,6] have
shown that there is a continual gradient of increased risk of
both death and disease progression associated with lower
CD4 cell counts and no specific clear threshold at which
risk increases.
The most frequent definition of late presentation for treat-
ment is a CD4 cell count below 200 cells/mm3, although
other thresholds have ranged from 50 to 350 cells/mm3
[1,7-18]. This has sometimes been combined with whether
an individual presented with an AIDS-defining diagnosis
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[19,20]. However, current UK guidelines recommend
initiation of antiretroviral therapy (ART) in all patients
with a CD4 cell count of less than 350 cells/mm3 [21]
and the European consensus is now that late presentation
for care refers to persons presenting with CD4 cell count
below 350 cells/mm3 or those presenting with an AIDS-
defining event regardless of CD4 count [20,22]. Two recent
studies have reported on late presentation using this
European consensus definition. In one of these studies,
73% of CD4 cell count at diagnosis were missing and
had to be imputed [23] while the other study examined
late presentation over a shorter period of time compared
to our study [24].
In this study, we examined factors associated with late
presentation (CD4 cell count < 350 cells/mm3), and
mortality in a large UK cohort comprising predominantly of
men who have sex with men (MSM) over a 14-year period.
Methods
Study participants
2038 patients aged over 18 years attended the sexual
health clinic in Brighton between 1 January 1996 and 31
May 2010. Excluded from the analyses for late presentation
were 493 (24.2%) patients with no documented baseline
CD4 cell count for reasons stated in Figure 1A and a
further 9 patients who had no documented date of HIV
diagnosis, leaving 1536 (75.4%) patients with a docu-
mented CD4 cell count within 3 months of diagnosis
eligible for this analysis.
For the analysis on mortality, 64 (3.5%) patients only
attended once and did not contribute to follow-up time,
while the dates of HIV diagnosis were missing for 9
patients leaving 1965 (96.4%) patients eligible for this
analysis (Figure 1B). Ethical approval was not sought for
this study as we utilized non-identifiable information
previously collected in the course of normal care. Written
informed consent was not required for the same reason
[25], however access to the clinic database was approved by
the HIV/Genitourinary Medicine Protocol Review Panel at
Brighton and Sussex University Hospitals NHS Trust.
Study/Clinic procedures
Patients testing HIV positive that were either diagnosed
within the clinic or referred from another facilty were
followed up at 3 monthly intervals. Demographic informa-
tion collected at first visit were age at HIV diagnosis, date
of HIV diagnosis, ethnicity and HIV risk group. The clinic
database also had information on whether patients had
been previously diagnosed elsewhere with HIV or not. This
information ensured that true baseline CD4 cell counts
were used for the analyses presented.
Patients initiating ART attended at 2, 6 and 10 weeks
for blood tests and saw a doctor at 4, 8 and 12 weeks
and 3 monthly subsequently after full suppression of the
HIV RNA viral load.
CD4 cell count and HIV viral load within 90 days of HIV
diagnosis were documented and subsequently measured at
3 monthly intervals in stable patients or more frequently at
the discretion of their physician. The causes of death were
entered into the clinic database from death certificates.
Causes of death were ascertained for patients who died out-
side a healthcare facility following a coroner post-mortem
examination and this was also entered into the clinic
database when the information became available.
A: Late presentation B: Mortality analysis
2038 enrolled from  
Jan 1996 to May 2010
9 had missing 
date of 
diagnosis
493 had missing baseline 
CD4 cell count
297 on HAART when      
transferred to cohort
100 on HAART 
within cohort but no 
documented baseline 
CD4.     
96 were not on  
HAART
1535 used for 
analysis of late 
presentation
2038 enrolled from 
Jan 1996 to May 2010
134 
deaths
9 had missing 
date of 
diagnosis 64 attended 
only at day of 
presentation so 
did not 
contribute to 
follow-up time
1965 used for 
analysis of mortality
127 deaths used 
for analysis 
7 deaths in 
this group 
excluded
Figure 1 Cohort construction.
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Statistical analyses
To examine the proportion that presented late by calendar
time stratified by age, calendar period of diagnosis was
categorized as 1996-2001, 2002-2005 and 2006-2010 so that
there were adequate numbers in each group for statistical
analyses. Mean and standard deviations were reported
for normally distributed variables, and median and
inter-quartile ranges were used for skewed distributions.
Frequencies and percentages were reported for categorical
exposure variables.
Factors associated with late presentation were assessed
using odds ratios (ORs) estimated using logistic regression.
The likelihood ratio test statistic was used to estimate
the p-values for association in the multivariable logistic
regression model.
We also examined for the median time to initiation of
HAART for the two age groups stratified by CD4 cell
count at presentation using the Kaplan-Meier approach.
For this analysis, patients were censored at the time
started HAART for those on treatment and time last
seen for those who remained untreated at the end of
follow-up.
To estimate mortality rates, participants were censored
at the earliest of: death, date last seen, or end of follow-up
(31 May 2010). Poisson regression modelling was used to
estimate survival probability. Patients who attended at
least once following the enrollment visit contributed
person-years (pyr) for the analyses. Age was the pri-
mary exposure when fitting the multivariable Poisson
regression model. This was adjusted for a priori con-
founders such as ethnicity and HIV risk group irrespective
of whether they acted as confounders in this study
or not. All analyses were carried out using STATA 11.0
(StataCorp, College Station, TX, USA).
Results
Characteristics of study patients
Of the 2038 patients enrolled with HIV infection between
January 1996 and May 2010, 1536 (75.4%) patients had
documented CD4 cell counts within 3 months of diagnosis
and formed the basis of the analysis on late presentation.
Of the 1536 patients, 1316 (86%) were male and 151 (9.8%)
were aged 50 years and older when diagnosed with HIV
infection. The median age at HIV diagnosis was 33.1 years
(IQR 27.8-38.7) and 54.8 years (IQR 52.0-60.0) respectively,
for those aged <50 and ≥50 years at diagnosis and 34.2
years (IQR 28.2-41.5) for the whole cohort.
The majority of the cohort were Caucasian (79.5%)
and MSM (73.8%). Of the 239 participants of African-
Caribbean ethnicity, 90% acquired their HIV through
heterosexual intercourse while 87% of Caucasians acquired
their HIV through homosexual intercourse. There was
no difference in the age and sex distributions of patients
with missing CD4 count at presentation (p = 0.74 and
0.41 respectively). Patients with missing information on
CD4 count were significantly more often heterosexual and
of African ethnicity (p = 0.007 and 0.008 respectively).
Factors associated with late presentation
Approximately half (49%) the cohort presented late with
a CD4 count less than 350 cells/mm3 at HIV diagnosis
and 23% (359/1536) presented with a CD4 count less
than 200 cells/mm3. The median CD4 cell count for late
and early presenters was 211 cells/mm3 (IQR 83-289)
and 527 cells/mm3 (IQR 423-659) with median ages of
35.9 years (IQR 29.7- 43.6) and 32.9 years (IQR 27.5- 39.0)
respectively.
On univariable analyses, late presentation was associated
with older age, being of non-Caucasian origin and being
either a female or male heterosexual (Table 1). On
multivariable analyses, older age (OR = 2.18; 95%CI:
1.52-3.12; Table 1), male heterosexual, ethnicity (OR = 2.64,
95%CI 1.75-3.97 for African vs Caucasian) and earlier
calendar period (OR = 0.62, 95%CI 0.48-0.81 for 2006-
2010 vs 1996-2001) remained significantly independently
associated with late presentation.
The proportion presenting late decreased from 57.1%
among those younger than 50 years in 1996-1998 to
38.5% in the 2008-2010 (Figure 2A; p-trend = 0.0001).
In contrast, among those over the age of 50 years, the
proportion of patients presenting late was constant over
time (Figure 2B; p-trend = 0.89).
There was also evidence of a difference in trends of
presenting late with sexual orientation. Among MSM,
51.3% presented late in 1996-2001 period, compared
with 42.4% in 2002-2005 and 39.1% in the 2006-2010
(p-trend = 0.0012). The corresponding proportions among
heterosexuals were 66.3%, 66.5% and 65.0% respectively
(p-trend = 0.78).
Median time to initiation of ART amongst those pre-
senting late in those 50 years or older compared to those
less than 50 years was 47 days (IQR 26.0- 131.0) and
98.0 days respectively (IQR 39.0 -476.0); p (log-rank
test) = 0.001 whilst amongst those presenting early it is
1041 days (IQR 467-1491) and 1236 day respectively
(IQR 607-2290); p (log-rank test) = 0.0001 (Figure 3).
Mortality
Overall 127 deaths occurred in 1965 patients between Jan
1996 and May 2010; 26 and 54 deaths were in individuals
presenting with CD4 cell count greater and less than
350 cells/mm3 respectively while 47 deaths occurred in
individuals with unknown CD4 cell counts before death.
64/127 (50.4%) of deaths were AIDS related death, and
were predominantly due to AIDS- related bacterial
pneumonia and pneumocystis jirovecii pneumonia (PCP)
as well as AIDS-related malignancies in both age groups.
34/127(26.8%) of deaths were non-AIDS related death,
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predominantly due to malignancies. The causes for the
remaining deaths were unspecified.
Overall mortality rate in the cohort after 8210.30
person years (pyrs) of follow up was 15.47 per 1000 pyrs
(95% CI: 13.00-18.41).
Early mortality
53/127 (41.7%) of deaths occurred within the first year of
follow up in cohort; 1/26(3.9%) in those presenting with
CD4 count greater than 350 cells/mm3, 23/54(42.6%) in
those with CD4 count less than 350 cells/mm3 and 29/47
(61.7%) in those with unknown CD4 count.
12/30 (40%) of deaths among individuals 50 years or
older occurred in the first 12 months of presentation.
None of these 12 deaths occurred in individuals with
CD4 count greater than 350 cells/mm3. 4/12(33.3%) and
8/12(66.7%) were in individuals with CD4 count less than
350 cells/mm3 and unknown CD4 count respectively.
41/97(42.3%) of deaths among individuals less than
50 years occurred in the first 12 months of presentation.
Table 1 Univariable and multivariable logistic regression of the association between age at diagnosis and other factors
with late presentation
N = 1536 Late presenters
N (%)
Early presenters
N (%)
Crude odd ratios
(95% CI)
p-value Multivariable odd
ratios (95% CI)
p-value
Age <0.001 <0.001
<50 658(47.5) 727(52.5) 1 1
>50 96(63.6) 55(36.4) 1.93(1.36-2.73) 2.18(1.52-3.12)
Ethnicity <0.0001 <0.0001
Caucasian 540 (44.2) 681(55.8) 1 1
African/Caribbean 170(71.1) 69(28.9) 3.10(2.30-4.20) 2.64(1.75-3.97)
Others 35(54.7) 29(45.3) 1.52(0.92-2.52) 1.57(0.93-2.64)
Unknown 9(75.0) 3(25.0) 3.78(1.02-14.04) 3.30(0.86-12.65)
Sex/Risk group
MSM 493(43.5) 641(56.5) 1 <0.0001 1 0.004
Female heterosexual 137(63.7) 78(36.3) 2.28(1.69-3.09) 1.27(0.85-1.90)
Male heterosexual 117(68.8) 53(31.2) 2.87(2.03-4.05) 2.00(1.37-2.93)
Others 7(41.2) 10(58.8) 0.91(0.34-2.41) 0.89(0.33-2.43)
Calendar period 0.005 0.002
1996-2001 220(54.5) 181(45.1) 1 1
2002-2005 282(49.8) 284(50.2) 0.82(0.63-1.06) 0.72(0.55-0.94)
2006-2010 252(44.3) 317(55.7) 0.65(0.51-0.85) 0.62(0.48-0.81)
MSM =men who have sex with men.
Figure 2 Proportion presenting late in different calendar periods according to age at diagnosis.
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Only 1 of these early deaths occurred in an individual with
CD4 cell count greater than 350 cells/mm3. 19/41(46.3%)
and 21/41(51.2%) of these deaths were in individuals with
CD4 count less than 350 cells/mm3 and Unknown CD4
count respectively.
Factors associated with mortality
Table 2 shows factors associated with mortality in the
cohort.
On Univariable analysis, individuals who were 50 years
or older at HIV presentation had a higher mortality
compared to younger adults-HR 2.70 (95% CI: 1.80-4.08).
Being diagnosed with a CD4 count <350 cells/mm3 was
associated with a doubling of mortality while ART was
associated with 37% reduction in mortality.
On multivariable analysis, older age, earlier calendar
period, and lower or unknown CD4 count were signifi-
cantly associated with increased mortality. ART was also
associated with a more marked reduction in mortality
after adjustments. The reduction in mortality on ART was
similar for the group who had been on it for less than 12
months with that of individuals who had been on it for
longer, hence only the combined results for being on ART
was shown. The decrease in mortality in the later calen-
dar periods was further explored because of the change
in UK guidelines in 2008 recommending the initiation
of treatment when CD4 <350 cells/mm3. Prior to this
ART was initiated at CD4 <200 cells/mm3. We observed
that there was no difference in the adjusted decrease in
mortality in the 3-year period preceding the change in
guidelines and the 2-year period following this, both
periods showing an 80% decrease in mortality (full
results not shown).
No statistical interaction was detected between age
at presentation and late presentation on mortality
(p-interaction = 0.67).
Discussion
In our study, 49% of those diagnosed with HIV were
late presenters according to the new consensus defin-
ition for late presentation and nearly one-quarter
presented with advanced HIV infection. The fre-
quency of late presentation is similar to that recently
reported from Germany and New Zealand of 49.5%
and 50% respectively using the new threshold of CD4
<350 [23,24]. In this UK cohort, factors associated
with late presentation were being older than 50 years,
male heterosexual, African ethnicity and being diag-
nosed in the earlier calendar periods. The trend sug-
gests HIV infection is increasingly being diagnosed
early in the whole cohort and this was largely due to
increased HIV testing in men who have sex with men
as described in another cohort [26] and in those less
than 50 years of age. The risk factors identified in
this study corroborate findings from similar studies
on late diagnosis [10,11,14,18,27].
We showed a progressive improvement in earlier
diagnosis with time in those diagnosed under the age of
Figure 3 Kaplan-Meier estimates of time to ART initiation by age and presentation CD4 groups.
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50 years but strikingly the likelihood of late presentation
in those over 50 years of age remained constant over
this 14-year period. The association of older age with
late presentation of HIV has also been identified in
other studies [11,13,14,19,28] that used other CD4 cell
count thresholds for late presentation. However we
know that individuals older than 50 years could have
lower CD4 cell counts as a result of the normal ageing
process even in the absence of HIV infection, so would
be more likely to be considered “late presenters” when
they acquire HIV infection.
A study from our group has shown that individuals older
than 60 years were less likely to be offered an HIV test even
in situations where an opt-out approach was adopted [29].
The failure of physicians to consider the possibility of
HIV infections in these patients and confusion between
symptoms of opportunistic infections and those of
common co-morbid conditions associated with ageing
further delays HIV diagnosis [30-32].
The association of African ethnicity with late presentation
is consistent with other studies [11,14] and may reflect the
fact that these groups of individuals are often marginalized
and hard to reach. This may be due to lack of knowledge
about HIV infection or reduced access to medical services
[33]. Nearly all the Africans in our study acquired HIV
infection through heterosexual intercourse, which could be
due to sexual relations within or outside of the UK. A
recent HPA report states that an increasing proportion
of heterosexual transmission are occurring within the
UK [34].
Trends suggest that early diagnosis of HIV infection is
improving in the whole cohort. From 1996-2001, 55% of
patients were diagnosed late using the current CD4
threshold, but this had dropped to 44% in the 2006-2010
calendar periods. This still represents a high burden of
late presentation. Some studies have shown that many
late presenters had suffered an HIV related illness, which
had been missed in an earlier contact with a healthcare
giver [9,35].
Being diagnosed with HIV with a CD4 cell count <350
and being older than 50 years of age were independently
associated with increased mortality.
Late presentation in our cohort is associated with a
tripling of mortality. This is the first study reporting a
Table 2 Impact of age at diagnosis and late presentation with HIV on mortality
N = 1965 Rate/1000 pyrs
(95% CI)
Univariable rate
ratio (95% CI)
p-value Multivariable rate
ratio (95% CI)
p-value
Age at HIV diagnosis (years) <0.0001 <0.0001
<50 13.16(10.79-16.06) 1 1
>50 35.65(24.92-50.98) 2.70(1.80-4.08) 2.88(1.88-4.40)
CD4 count at diagnosis Cells/mm3 <0.0001 <0.0001
>350 7.59(5.16-11.14) 1 1
<350 16.65(12.75-21.74) 2.19(1.37-3.50) 2.99(1.80-4.95)
Unknown 30.53(22.94-40.63) 4.02(2.49-6.50) 6.60(3.86-11.28)
Calendar period <0.0001 <0.0001
1996-2001 42.61(31.81-57.06) 1 1
2002-2005 12.91(9.13-18.26) 0.30(0.19-0.48) 0.37(0.23-0.58)
2006-2010 10.69(8.10-14.11) 0.25(0.17-0.38) 0.31(0.21-0.47)
Sex/HIV risk group 0.06 0.43
MSM 14.20(11.53-17.50) 1 1
Female heterosexual 12.73(7.39-21.93) 0.90(0.50-1.61) 0.90(0.46-1.78)
Male heterosexual 26.16(17.54-39.03) 1.84(1.17-2.89) 1.45(0.90-2.35)
Others 26.16(6.54-104.60) 1.84(0.45-7.48) 1.26(0.31-5.14)
Ethnicity 0.09 0.04
Caucasian 15.21(12.56-18.41) 1 1
African/Caribbean 12.53(7.28-21.58) 0.82(0.46-1.47) 1.05(0.53-2.10)
Others 33.55(17.46-64.49) 2.21(1.12-4.36) 2.78(1.37-5.62)
ART status 0.01 <0.0001
Not on ART 20.81(15.81-27.38) 1 1
On ART 13.20(10.54-16.52) 0.63(0.44-0.90) 0.33(0.22-0.50)
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tripling of mortality with the higher CD4 count threshold
for late presentation.
The association of late presentation with increased
mortality has also been described in other studies both
in the UK [18,36,37] and in other countries such as
Spain [38], the Netherlands [39] and France [40]. These
studies differ from ours in that they have used different
CD4 cell count thresholds for defining late presentation
most commonly a CD4 count less than 200 cells/mm3.
Individuals diagnosed late are usually more likely to
present with multiple HIV-related complications as
well as have a higher risk of immune reconstitution
inflammatory syndrome (IRIS), with a likely associated
increase in mortality.
The strengths of this study lie in the utilization of the
new European consensus definition for late presentation
as this would facilitate regional comparisons within
Europe and allow investigation of temporal trends after
interventions [22], and the duration of the study period
(14 years) which allowed a robust estimate of trends as
well as large sample size. The study however has some
limitations. The age at seroconversion was missing for
the majority of the cohort; hence age at cohort entry
(presentation) has been used. Age at entry is the sum of
age at seroconversion and time since seroconversion
[41,42], both of which are strong predictors of disease
progression and death. In our study it was not possible
to separate their two effects without knowledge of the
date of seroconversion. We did not separate the effect of
background mortality which is higher in older individ-
uals from that associated with the additional effect of
HIV infection. However, in individuals within the same
age group, those presenting with lower CD4 cell count
had a higher short-term mortality and this was more
likely to be attributable to the effect of HIV itself rather
than the effect of ageing of the cohort. In the author’s
experience, some individuals with “missing” CD4 count
at presentation (significantly more African and hetero-
sexual risk group in this cohort) were those admitted
through the emergency department in Brighton because
of presentation with advanced HIV. Their CD4 counts,
although in the hospital system did not always follow
through to the clinic database which is different. We
showed that these individuals have a higher mortality
(unknown CD4 category), hence mortality would have
been underestimated in those with CD4 <350 cells/mm3.
Some deaths were coded as unspecified especially in
those who died outside healthcare facilities as further
information was lacking. This could have resulted in
misclassification of some causes of deaths. Finally, the
majority of the patients in this cohort were Caucasian
MSM, hence the findings cannot be generalised to a cohort
that is diverse in both ethnicity and sexual orientation;
however this does not undermine the study validity.
As a result of the high mortality associated with late
diagnosis, strategies must be put in place to encourage
HIV testing. The CDC recommend routine testing in all
healthcare settings for patients aged 13–64 years, unless the
local HIV prevalence is known to be less than 0.1% [43].
In addition to recommending routine testing in
genitourinary medicine and antenatal clinics, 2008 UK
guidelines for HIV testing also advocate that tests should
be offered to all adults registering in general practice
and to all general medical admissions patients in areas
where diagnosed HIV prevalence is greater than 2 per
1,000 among 15 to 59 year olds [44]. The UK guidelines
have the advantage of not having any age restrictions but
restricting HIV testing to only general medical admissions
in hospitals within areas of high prevalence has been shown
to miss the majority of HIV infections in one study [29].
HIV testing should take an ‘opt-out’ approach. Higher
rates of HIV testing are achieved with such ‘opt-out’
approaches than opt-in approaches [45,46]. Identifying
high-risk groups who continually refuse an HIV test and
addressing the reasons for this could also encourage
earlier diagnosis. One of the mains reasons for refusing
a test is the stigma associated with HIV infection. To
overcome the issue of stigma, we need to avoid the
approach of offering an HIV test to only individuals
perceived to be at high risk and ‘normalize’ the test by
offering it to everyone alongside a battery of other rou-
tine investigations. Early HIV diagnosis could result in
reduction of onward transmission as individuals aware
of their HIV infection would be more likely to modify
their sexual behaviours [47]. Furthermore, the use of
HAART can also reduce an individual’s infectiousness by
reducing plasma and genital HIV viral loads [48,49]. The
findings of this study re-enforce the need for a universal
HIV testing policy. General practitioners and hospital
physicians should always be aware of the possibility of
HIV infection in their patients irrespective of their age
and there should be a policy that enables HIV test to be
offered routinely alongside other investigations.
Conclusion
This paper showed that HIV late presentation is very
common and does not appear to be improving in older
adults. This impacts individual health as documented by
increased mortality in this study. The consequent increase
in hospitalizations also results in increased health care
costs. Most HIV transmissions are from individuals
unaware of their status.
Prompt HIV diagnosis could be achieved through a
policy that enables HIV test to be offered routinely
alongside other investigations.
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